Change in activity participation compared to the baseline for normal workdays. by Sebastian A. Müller (10688740)

Reproduction number <i>R</i>(<i>t</i>) for the duration of the simulation. by Sebastian A. Müller (10688740)

Simulations with reductions of activity participation as obtained from mobility data. by Sebastian A. Müller (10688740)

Normalized contact intensities <i>ci</i>′, relative to the contact intensity at home, . by Sebastian A. Müller (10688740)

Outdoors fraction for activities of type leisure, depending on the temperature of each day. by Sebastian A. Müller (10688740)

Final model. by Sebastian A. Müller (10688740)

How duration (in hours) translates into the infection probability for two different contact intensities. by Sebastian A. Müller (10688740)

Disease progression model. by Sebastian A. Müller (10688740)

Contributions to <i>R</i> by activity type and intervention according to our model. by Sebastian A. Müller (10688740)

Average time consumption of out-of-home activities. by Sebastian A. Müller (10688740)

Disease import over time. by Sebastian A. Müller (10688740)

Unrestricted base case. by Sebastian A. Müller (10688740)

Events for travel. by Sebastian A. Müller (10688740)

VANGL2 recruits MARCH8 to promote the K27-linked ubiquitination of NLRP3. by Huaji Jiang (16907514)

Increased ROS level decreases RLS in respiratory-deficient cells. by Dae-Gwan Yi (5410298)

Proline is toxic in cells unable to catabolize it. by Fitz Gerald S. Silao (9384713)

Flow chart. by Raphaele Houlbracq (20558509)

“…The difference in overall prevalence of OASI between 2010 (0.7%) and 2021 (1.0%) was not statistically significant after adjustment (aRR 1.24, 95% CI 0.91 to 1.68). By groups of classification, the prevalence of OASI increased significantly only in Group 2b [nulliparous term cephalic singleton with spatula delivery] from 2.6% (95% CI 1.2 to 5.6) in 2010 to 9.6% (95% CI 6.2 to 14.7) in 2021 (aRR 3.69, 95% CI 1.50 to 9.09), and did not differ statistically significantly in Group 2a [nulliparous term cephalic singleton with forceps delivery] from 3.2% (95% CI 1.8 to 5.7) in 2010 to 5.7% (95% CI 3.4 to 9.5) in 2021 (aRR 1.78, 95% CI 0.81 to 3.90).…”

Gefitinib + Capmatinib decrease proliferation of <i>v-ras</i>^<i>Ha</i>-transduced wild type and <i>Tpl2</i>^-/- keratinocytes. by Mary B. Kelley (12290071)

Data used to generate Fig 5. by Pattamaporn Kittayapong (289542)

“…However, this irradiation dose could be reduced to 5 Gy to sterilize both males and females infected with <i>Wolbachia</i>. …”

Data used to generate Table 5. by Pattamaporn Kittayapong (289542)

“…However, this irradiation dose could be reduced to 5 Gy to sterilize both males and females infected with <i>Wolbachia</i>. …”